Daewoong Co., Ltd. (KRX:003090)
21,800
+150 (0.69%)
At close: Nov 3, 2025
Daewoong Revenue
Daewoong had revenue of 528.43B KRW in the quarter ending June 30, 2025, with 11.65% growth. This brings the company's revenue in the last twelve months to 2.03T, up 11.17% year-over-year. In the year 2024, Daewoong had annual revenue of 1.94T with 6.79% growth.
Revenue (ttm)
2.03T
Revenue Growth
+11.17%
P/S Ratio
0.44
Revenue / Employee
5.36B
Employees
379
Market Cap
887.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.94T | 123.08B | 6.79% |
| Dec 31, 2023 | 1.81T | 116.50B | 6.86% |
| Dec 31, 2022 | 1.70T | 185.96B | 12.30% |
| Dec 31, 2021 | 1.51T | 156.04B | 11.51% |
| Dec 31, 2020 | 1.36T | -10.34B | -0.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |